Memantine in the treatment of obsessive-compulsive disorder

Memantine as adjuvant therapy in the treatment of severe OCD: a double blind randomized trial Effect of

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106031556N22

Enrollment

Registered

2011-06-12

Start date

2011-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Tablet fluvoxamine (200 mg/day) combined with 20 mg/day of Tablets memantin as intervention group for 8 weeks. Intervention 2: Tablet fluvoxamine (200 mg/day) combined with placebo as

Treatment - Drugs

Placebo

Tablet fluvoxamine (200 mg/day) combined with 20 mg/day of Tablets memantin as intervention group for 8 weeks

Tablet fluvoxamine (200 mg/day) combined with placebo as control group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1-Age between 18-60, 2-Diagnosis of OCD based on DSM IV 3 , Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale- Exclusion Criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious cardiac, renal or hepatic disease ,5- receiving psychotropic medications during the last 6 weeks 6- pregnancy orbreast feeding 7-rising liver transaminases to three times the upper limit of normal or higher

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Y_BOCS.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026